Activity of RX-04 pyrrolocytosine protein synthesis inhibitors against multidrug-resistant gram-negative bacteria

Anna Vickers, Shazad Mushtaq, Neil Woodford, Michel Doumith, David M Livermore

Research output: Contribution to journalArticlepeer-review

4 Citations (Scopus)
18 Downloads (Pure)


Pyrrolocytosines RX-04A-D are designed to bind to the bacterial 50S ribosomal subunit differently from currently-used antibiotics. The four analogs had broad anti-Gram-negative activity: RX-04A inhibited 94.7% of clinical Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa at 0.5-4 μg/ml, with no MICs >8 μg/ml. MICs for multi-resistant carbapenemase producers were up to two-fold higher than for control strains, with values ≥8 μg/ml for one Serratia isolate with porin and efflux lesions. mcr-1 did not affect MICs.
Original languageEnglish
Pages (from-to)e00689-18
JournalAntimicrobial Agents and Chemotherapy
Issue number8
Early online date18 Jun 2018
Publication statusPublished - Aug 2018

Cite this